In light of the indispensable role of general practitioners and clinicians in detecting, diagnosing and publicly reporting adverse drug reactions, this means a very big threat to public safety.” For the study, Spelsberg and colleagues made freedom of information requests to three regulatory authorities responsible for registering post-marketing studies in Germany and obtained data on 558 studies.